RETRACTED ARTICLE: MicroRNA-939 Directly Targets HDGF to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/β-Catenin Pathway

Abstract

Situ J, Zhang H, Jin Z, Li K, Mao Y, Huang W. Onco Targets Ther. 2020;13:4257–4270.

The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised over alleged image duplication in Figure 8A with similar images from unrelated articles, specifically:

• Figure 8A appears to have been duplicated with a similar image in Figure 6A from Chen et al, 2019 (https://doi.org/10.3892/ijmm.2019.4429).

The authors did not respond to our queries and the Editor determined the findings of the study were no longer valid and advised for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Keywords:

• microRNA-939
• prostate cancer
• hepatoma-derived growth factor
• WNT/β-catenin signaling

View retraction statement:

MicroRNA-939 Directly Targets HDGF to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/β-Catenin Pathway [Retraction]